HTGF | High-Tech Gruenderfonds

Hema.to is a developer of clinical support software that specializes in automated, AI-powered detection suggestions for blood cancer, utilizing flow cytometry data. The company's platform offers comprehensive decision support, taking users from raw flow files to complete diagnostic reports. By focusing on the needs of hematology laboratories, Hema.to aims to enhance operational efficiency while ensuring high-quality results. Its tools are specifically designed to meet the unique requirements of clinical flow, empowering labs to provide better patient care through advanced technology.

Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform offers user-friendly software that supports healthcare staff in their daily operations while facilitating the integration of innovative technologies such as artificial intelligence, big data, telemedicine, patient applications, and wearables. By streamlining workflows and automating various tasks, Avelios Medical aims to significantly improve both patient outcomes and healthcare research, making it a valuable resource for hospitals and clinics seeking to modernize their services.

Mediaire GmbH, founded in 2018 and based in Berlin, Germany, specializes in developing software solutions for medical imaging in the field of radiology. The company's flagship application, md.Brain, provides quantitative brain volumetry reports aimed at early detection of senile dementia and the automated measurement of medullary lesions associated with multiple sclerosis. By utilizing artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, delivering precise examination results and diagnostic suggestions. This software is locally installed and is primarily targeted at radiologists and healthcare centers, improving the quality and speed of diagnostic and therapeutic procedures.

Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.

CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.

InContAlert is a deep tech start-up focused on improving the lives of individuals with bladder dysfunction through innovative medical technology. The company has developed an mHealth device that allows users to monitor the filling level of their urinary bladder without the need for catheters or frequent intervention from healthcare professionals. The device, which can be fastened using a belly band or clipped to underwear, features a sensor positioned just above the pubic bone to continuously measure bladder levels. This data is transmitted to an accompanying app, which alerts users when a predefined filling level is reached, thereby reducing the risk of uncontrolled urine loss and preventing harmful bladder distension. By leveraging deep learning algorithms for data analysis, InContAlert empowers incontinence patients to regain control and enjoy a more carefree lifestyle.

DNTOX operates a bioanalytical testing laboratory focused on animal-free screening of chemicals, particularly for their potential to disrupt brain development and cause developmental neurotoxicity. The laboratory utilizes an in vitro testing battery based on human cell models, which facilitates high-content and medium-throughput chemical screening. This process is enhanced by proprietary software that employs artificial intelligence, aiding clients in the chemical, pharmaceutical, and cosmetics industries. DNTOX supports its customers in identifying safe lead structures during substance development and conducting safety assessments during the approval and re-approval processes of chemicals. The company's commitment to innovation aims to promote the use of safe chemicals without the reliance on animal testing.

Hema.to is a developer of clinical support software that specializes in automated, AI-powered detection suggestions for blood cancer, utilizing flow cytometry data. The company's platform offers comprehensive decision support, taking users from raw flow files to complete diagnostic reports. By focusing on the needs of hematology laboratories, Hema.to aims to enhance operational efficiency while ensuring high-quality results. Its tools are specifically designed to meet the unique requirements of clinical flow, empowering labs to provide better patient care through advanced technology.

Nia Health specializes in developing digital health applications that focus on dermatological conditions, particularly atopic dermatitis and psoriasis. The company utilizes an innovative MedTech platform to create personalized medical software that addresses the unique needs of each patient. Nia Health's AI-powered app offers tailored support and relief for individuals suffering from eczema, combining clinically validated content with features designed to enhance patient engagement. Originating from Charité Universitätsmedizin Berlin, the company aims to improve patient outcomes by providing effective treatments for chronic skin conditions while reducing the stigma associated with them. Nia Health has garnered significant funding, and its app is reimbursed by major health insurance providers in Germany.

Mbiomics is a biotechnology company focused on microbiome research, diagnostics, and therapeutics. It has developed a high-throughput, low-cost platform that allows for dynamic and real-time analysis and quantification of the human gut microbiome. By providing informed precision diagnostics and targeted therapies, Mbiomics aims to enhance patient outcomes and promote healthier living through innovative approaches.

HBOX Therapies is a developer of technology that facilitates the lung-protective treatment of respiratory patients. They produce miniaturized hyperoxygenation therapies. The technology's application is miniature respiratory assistance for patients suffering from lung failure.

Neotiv GmbH, founded in 2017 and headquartered in Magdeburg, Germany, specializes in mobile software solutions aimed at monitoring memory function and supporting individuals with dementia. The company offers memory tests designed to assess brain regions affected by aging and early Alzheimer's disease. Its health monitoring application not only tracks users' memory performance over time but also provides insights derived from scientific research, making them accessible to a wider audience. By combining neurodegenerative disease research with its digital platform, Neotiv enables healthcare professionals and researchers to enhance early detection and management of memory-related issues.

Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.

C-mo Medical Solutions specializes in developing monitoring devices aimed at providing a comprehensive assessment of cough patterns in patients. The company's portable and ergonomic wearables facilitate long monitoring periods and the detection of distinctive cough patterns. With fully automated analysis capabilities, these devices enable healthcare professionals to deliver accurate diagnoses and prescribe personalized treatment plans. By addressing key use-cases throughout the patient management lifecycle, C-mo Medical Solutions plays a significant role in enhancing cough-related healthcare.

Noscendo GmbH is a diagnostics company based in Duisburg, Germany, specializing in bioinformatics solutions for the identification and assessment of pathogens associated with bloodstream infections. The company utilizes Next Generation Sequencing (NGS) to enable intensive care clinicians to detect bacteria, fungi, viruses, and parasites from a single standard blood draw, without the need for prior cultivation or detailed knowledge of the infection's nature. Its proprietary algorithms assess the relevance of each identified pathogen, allowing for precise differentiation between commensals, contamination, and actual infection. Noscendo's innovative platform aims to enhance the efficiency and accuracy of pathogen detection in clinical settings.

Ebenbuild is a health tech company that utilizes advanced research from TU Munich to develop a platform focused on respiratory diseases. The company offers a deep tech solution that includes two initial applications aimed at enhancing drug development and patient care. One application focuses on digital trials, enabling biotech and pharmaceutical companies to optimize drug delivery to the lungs through predictive models, thereby reducing risks and accelerating clinical development. The second application integrates with hospital IT systems to provide precise, actionable intelligence at the patient bedside, particularly for individuals with Acute Respiratory Distress Syndrome (ARDS). This technology personalizes mechanical ventilation settings, improving both short-term and long-term patient outcomes. By continuously expanding its platform to address various medical indications, Ebenbuild aims to deliver significant benefits to patients, healthcare providers, and payors.

M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.

Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform offers user-friendly software that supports healthcare staff in their daily operations while facilitating the integration of innovative technologies such as artificial intelligence, big data, telemedicine, patient applications, and wearables. By streamlining workflows and automating various tasks, Avelios Medical aims to significantly improve both patient outcomes and healthcare research, making it a valuable resource for hospitals and clinics seeking to modernize their services.

Mediaire GmbH, founded in 2018 and based in Berlin, Germany, specializes in developing software solutions for medical imaging in the field of radiology. The company's flagship application, md.Brain, provides quantitative brain volumetry reports aimed at early detection of senile dementia and the automated measurement of medullary lesions associated with multiple sclerosis. By utilizing artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, delivering precise examination results and diagnostic suggestions. This software is locally installed and is primarily targeted at radiologists and healthcare centers, improving the quality and speed of diagnostic and therapeutic procedures.

Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.

Loewi GmbH, established in 2019 and based in Munich, Germany, operates an online platform that specializes in the sale of non-pharmacy medical products, including medical self-tests and health products. As a scientific spin-off from the Technical University of Munich, Loewi aims to make personalized health and nutrition accessible to a broader audience. The company emphasizes a healthy and active lifestyle by offering personalized diet recommendations and supplements tailored to individual needs based on test results. With a strong focus on scientific evidence and data-driven personalization, Loewi leverages methods developed and tested in competitive sports to analyze nutrient requirements and help customers achieve their health goals. The integration of science and technology underpins Loewi's operations, and the company collaborates with leading universities and research institutions to advance the industry.

PXL Vision AG, founded in 2017 and headquartered in Zurich, Switzerland, specializes in the design and development of identity verification and customer onboarding software solutions. Its flagship product, Daego, employs advanced computer vision and machine learning technologies to create trusted digital identities. This cross-platform solution is tailored to meet the needs of various industries, including insurance, fintech, and healthcare, by automating the verification of identity documents and performing facial biometric checks to ensure that users are legitimate and the rightful owners of their documents. By facilitating secure and efficient customer onboarding, PXL Vision aims to enhance conversion rates, reduce costs associated with compliance, and mitigate identity fraud. With research and development centers in Novi Sad, Serbia, and Yerevan, Armenia, PXL Vision is dedicated to establishing a foundation of trust in digital interactions through unbiased and verifiable identities.

Noscendo GmbH is a diagnostics company based in Duisburg, Germany, specializing in bioinformatics solutions for the identification and assessment of pathogens associated with bloodstream infections. The company utilizes Next Generation Sequencing (NGS) to enable intensive care clinicians to detect bacteria, fungi, viruses, and parasites from a single standard blood draw, without the need for prior cultivation or detailed knowledge of the infection's nature. Its proprietary algorithms assess the relevance of each identified pathogen, allowing for precise differentiation between commensals, contamination, and actual infection. Noscendo's innovative platform aims to enhance the efficiency and accuracy of pathogen detection in clinical settings.

Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of custom orthopedic aids, including orthoses and prostheses. The company empowers orthopedic and prosthetic (O&P) professionals through its Mecuris Solution Platform, which integrates digital technology and 3D printing. This platform allows for the co-creation of individualized O&P products by utilizing patient data and scans to semi-automatically generate custom 3D designs. These designs can be printed locally, ensuring a tailored fit and reducing production times by up to 75%. Mecuris aims to enhance the lives of wearers by providing quick, personalized solutions that meet their specific needs.

M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.

miRdetect GmbH is a Bremen-based company that specializes in the development and marketing of in-vitro diagnostics for cancer detection. Founded in 2016, the company offers products such as miRcontrol GCT, a test kit specifically designed for the detection of testicular cancer. miRdetect focuses on creating and manufacturing molecular biological tests that enable the early identification and diagnosis of various cancers by accurately detecting minute quantities of nucleic acids. In addition to its existing products, the company is actively engaged in research and development to expand its portfolio of diagnostic tests.

Mediaire GmbH, founded in 2018 and based in Berlin, Germany, specializes in developing software solutions for medical imaging in the field of radiology. The company's flagship application, md.Brain, provides quantitative brain volumetry reports aimed at early detection of senile dementia and the automated measurement of medullary lesions associated with multiple sclerosis. By utilizing artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, delivering precise examination results and diagnostic suggestions. This software is locally installed and is primarily targeted at radiologists and healthcare centers, improving the quality and speed of diagnostic and therapeutic procedures.

Plasmion GmbH, founded in 2016 and based in Augsburg, Germany, specializes in the development of ionization devices for various scientific and industrial applications. The company's flagship product, the SICRIT SC-20X, includes a control unit and ion source, facilitating quality control in diverse fields such as food safety, medical diagnostics, security, forensics, and emission monitoring. Plasmion is at the forefront of innovative sensor technology, utilizing ambient mass spectrometry to enhance analytical capabilities in both laboratory settings and industrial process control. This technology aims to improve sensitivity and selectivity, addressing the limitations of traditional sensors and enabling real-time measurements in various applications. The company serves a global clientele through a network of sales partners, making significant strides in advancing the use of electronic nose technology.

Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of custom orthopedic aids, including orthoses and prostheses. The company empowers orthopedic and prosthetic (O&P) professionals through its Mecuris Solution Platform, which integrates digital technology and 3D printing. This platform allows for the co-creation of individualized O&P products by utilizing patient data and scans to semi-automatically generate custom 3D designs. These designs can be printed locally, ensuring a tailored fit and reducing production times by up to 75%. Mecuris aims to enhance the lives of wearers by providing quick, personalized solutions that meet their specific needs.

OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.

Asana Rebel, established in 2015, is a Berlin-based company that develops a mobile application focused on improving the health and wellbeing of women. It offers a unique blend of yoga and fitness workouts, with a library of themed exercises and personalized plans. The app is available in six languages and has been recognized as one of the top health and fitness apps, with an average rating of over 4.6 stars.

advanceCOR GmbH is a drug development company based in Munich, Germany, specializing in therapeutics and diagnostics for heart and vascular diseases. Founded in 2000, the company focuses on creating personalized treatments and has developed several innovative products. Notable among these is Revacept, a human Fc fusion protein that inhibits the local activation of platelets at vascular injury sites. Additionally, advanceCOR offers COR-2, a recombinant protein that reduces foam cell generation and cholesterol uptake, and COR-3, which targets atherosclerotic plaques while binding to progenitor cells to promote plaque healing. The company’s product pipeline also includes therapies for acute arterial thrombosis, myocardial infarction, stroke, and transient ischemic attack, emphasizing its commitment to addressing serious cardiovascular conditions.

M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.

Neotiv GmbH, founded in 2017 and headquartered in Magdeburg, Germany, specializes in mobile software solutions aimed at monitoring memory function and supporting individuals with dementia. The company offers memory tests designed to assess brain regions affected by aging and early Alzheimer's disease. Its health monitoring application not only tracks users' memory performance over time but also provides insights derived from scientific research, making them accessible to a wider audience. By combining neurodegenerative disease research with its digital platform, Neotiv enables healthcare professionals and researchers to enhance early detection and management of memory-related issues.

Asana Rebel, established in 2015, is a Berlin-based company that develops a mobile application focused on improving the health and wellbeing of women. It offers a unique blend of yoga and fitness workouts, with a library of themed exercises and personalized plans. The app is available in six languages and has been recognized as one of the top health and fitness apps, with an average rating of over 4.6 stars.

KSK Diagnostics GmbH, established in 2014 and based in Hamburg, Germany, specializes in the development of molecular point-of-care diagnostic assays aimed at diagnosing infectious diseases and cancer. The company utilizes isothermal amplification technology to create rapid tests that enable healthcare professionals to make timely diagnoses, often within 30 minutes, thereby facilitating prompt treatment decisions. In addition to its diagnostic assays, KSK Diagnostics offers customizable services, including the development of nucleic acid-based tests using real-time PCR or RT-PCR, as well as verification and validation studies and product enhancement services for other organizations in the healthcare sector. As a pioneer in this field, KSK Diagnostics is dedicated to improving patient-oriented diagnostics through innovative technologies.

M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.

Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of custom orthopedic aids, including orthoses and prostheses. The company empowers orthopedic and prosthetic (O&P) professionals through its Mecuris Solution Platform, which integrates digital technology and 3D printing. This platform allows for the co-creation of individualized O&P products by utilizing patient data and scans to semi-automatically generate custom 3D designs. These designs can be printed locally, ensuring a tailored fit and reducing production times by up to 75%. Mecuris aims to enhance the lives of wearers by providing quick, personalized solutions that meet their specific needs.

Bentekk GmbH, founded in 2014 and based in Hamburg, Germany, specializes in the development and manufacture of intelligent gas measuring systems aimed at on-site analysis of contaminants. The company produces portable gas measurement devices that utilize gas chromatography and photo ionization detection for the assessment of volatile organic compounds, including hazardous substances like benzene. These devices are designed to enhance occupational health and safety across various sectors, including environmental monitoring, emergency response, logistics, life sciences, and the chemical industry. By providing accurate and rapid measurements of toxic gases, Bentekk supports improved safety and compliance with threshold limit values, contributing to a safer working environment. As of April 2017, Bentekk operates as a subsidiary of Dräger Safety AG & Co. KGaA.

Asana Rebel, established in 2015, is a Berlin-based company that develops a mobile application focused on improving the health and wellbeing of women. It offers a unique blend of yoga and fitness workouts, with a library of themed exercises and personalized plans. The app is available in six languages and has been recognized as one of the top health and fitness apps, with an average rating of over 4.6 stars.

SeNostic is a diagnostics company focused on developing innovative in vitro diagnostic tests for neurodegenerative disorders. The company aims to provide precise and accurate early differential diagnoses for various neurodegenerative conditions, enhancing the ability to identify specific diseases. SeNostic also specializes in offering biochemicals for neuroscience research and has created a novel method to amplify and characterize disease-specific protein aggregates found in tissues and body fluids. This approach enables better patient outcomes by facilitating timely and appropriate treatment for those affected by neurodegenerative diseases.

LifeTime is a digital health application developed by connected-health.eu GmbH since 2014, which has established itself as a leading and secure solution for the digital management and transmission of medical data. The application facilitates the efficient and accurate exchange of medical documents, including findings and images, between healthcare professionals and patients. By enabling secure digital communication, LifeTime enhances the clarity of health and treatment histories for users, streamlining workflows for doctors and medical staff. In 2019, LifeTime GmbH acquired the platform, signaling a new phase of development and enhancement under its management.

OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.

Preventicus GmbH, founded in 2014 and headquartered in Jena, Germany, develops innovative health solutions that utilize smartphone and smartwatch technologies to monitor vital parameters. The company's main product, Preventicus Heartbeats, is a class I medical device designed to identify atrial fibrillation, a condition that increases the risk of stroke. This smart screening solution allows users to check their heart rhythm quickly and conveniently, requiring no additional accessories. The software applications are certified medical devices and have demonstrated a level of accuracy previously achievable only by physicians, making them valuable for private users, corporate clients in occupational health management, and OEM customers. Preventicus focuses on early preclinical risk screening for lifestyle-related illnesses, including heart attacks and strokes, effectively enhancing personal health management.

Predemtec GmbH, founded in 2011 and based in Hennigsdorf, Germany, specializes in developing diagnostic tests aimed at identifying risk factors for dementia and related illnesses. The company's primary product, Predemtec DX, is a serum-based immunoassay designed for the early detection and risk assessment of senile dementia, particularly in Alzheimer's disease and mild cognitive impairment patients. This diagnostic procedure utilizes a blood sample to analyze the concentration of six biomarkers through a specific algorithm, allowing healthcare providers to generate risk profiles. By offering these insights, Predemtec aims to help delay the onset of dementia and reduce its severity.

EGYM is a global fitness technology company that specializes in providing intelligent workout solutions for fitness and health facilities. The company offers a comprehensive platform that integrates connected gym equipment and software, enabling operators to enhance the workout experience for their members. EGYM's offerings include a B2B corporate fitness subscription solution tailored for employers, as well as personalized, data-driven fitness experiences for users. This approach supports individuals in achieving their fitness goals, whether related to muscle gain, performance, or rehabilitation. EGYM's commitment to member success is reflected in its belief that the success of gym operators is intrinsically linked to the progress of their members towards improved physical and mental wellness.

OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.

Synoste Oy, founded in 2007 and based in Espoo, Finland, specializes in developing innovative solutions for the treatment of skeletal deformities. The company focuses on patient-friendly technologies for various conditions, including congenital limb discrepancies, trauma-related injuries, and craniomaxillofacial deformities. Its flagship product is a third-generation limb-lengthening system that incorporates smart materials, designed to enhance patient comfort during the often-complicated lengthening procedure. This advanced device aims to reduce complications and facilitate quicker recovery, making it a significant improvement over traditional methods. As a subsidiary of Globus Medical, Inc., Synoste continues to advance its mission of providing effective and less painful treatment options for individuals with skeletal deformities.

Photonics Healthcare GmbH is a medical device company based in Garching, Germany, specializing in the development and commercialization of clinical monitors for measuring cellular oxygen levels. Its primary product, the COMET Monitor, enables healthcare professionals to non-invasively assess cellular oxygen metabolism, including both availability and consumption, at the bedside. This technology is crucial for detecting hypoxia in tissue cells, allowing doctors to evaluate tissue vitality and make informed decisions regarding treatment interventions. By providing real-time data on cellular oxygen dynamics, Photonics Healthcare supports the timely prevention of organ failure and aims to enhance patient care. Additionally, the company offers contract research programs to further advance its medical technologies.

AYOXXA Biosystems GmbH is a life science tools company based in Cologne, Germany, with additional offices in Singapore and Boston, Massachusetts. Founded in 2010, AYOXXA specializes in developing a proprietary technology platform for multiplexed protein analysis. This platform, which utilizes In-situ Encoded Bead-based Arrays, enables users to simultaneously measure multiple protein markers associated with various health conditions, including cancer, allergies, cardiovascular diseases, and infectious diseases. AYOXXA's innovative biochips merge biological analysis with information technology, expanding the potential applications in biomedical research. The company also offers biomarker kits to facilitate the identification and quantification of proteins and other biomolecular analytes.

Epivios GmbH, founded in 2011 and based in Düsseldorf, Germany, specializes in molecular diagnostics aimed at the early detection of bladder and prostate cancer. As a spin-off from Heinrich Heine University, the company has an interdisciplinary team of doctors and biologists who have been developing innovative epigenetic procedures for cancer diagnosis since 2009. Epivios has created a unique epigenetic platform technology that features a novel standardization tool, allowing for the comparison of samples with varying genetic constitutions. This advancement enables more accurate analysis of genetic sequences across the entire genome, contributing to improved diagnostic capabilities in the field of oncology.

OakLabs GmbH is a research firm based in Hennigsdorf, Germany, specializing in integrated business solutions for the biotechnology and medical technology sectors. Founded in 2011 by Martina Schad, the company offers a range of services including custom SNP genotyping, DNA marker analysis, and consulting. Its expertise encompasses biocomputing, which involves sequence analysis, genomic selection, and biomolecule simulation, as well as MyArray services that include XL-design development and RNA/DNA sample hybridization. OakLabs also develops dedicated algorithms for the identification and analysis of DNA markers, linking them to specific traits in various sequenced organisms. Additionally, the company provides training, maintenance, and algorithm enhancement services to support its clients in the field.

Eyesight & Vision GmbH, founded in 2010 and based in Nürnberg, Germany, specializes in the development and marketing of advanced diagnostic equipment for refractive errors during cataract surgery. The company’s flagship product, the Intraoperative Ocular Wavefront Aberrometer (I-O-W-A), enables surgeons to optimize the selection and positioning of intraocular lenses (IOLs) with enhanced predictability of refractive outcomes and improved patient satisfaction. Utilizing patented "flying spot" technology, the system provides real-time measurements of refractive power and incorporates binocular input reflection through a 3D Head-Up Display, ensuring seamless integration with existing surgical microscopes. This innovative approach facilitates efficient and accurate measurements during surgery, ultimately contributing to better surgical results.

Humedics GmbH, founded in 2009 and based in Berlin, Germany, specializes in the development of a breath analysis device designed to assess liver function in patients suffering from liver failure. The company's key product, the LiMAx test, is a diagnostic system that includes a medical device, breath masks, and a diagnostic drug, enabling clinicians to quantitatively evaluate individual liver function. This technology supports various applications, such as assessing liver function before and after transplantation, planning liver surgeries, and evaluating conditions like liver cirrhosis. By providing rapid and precise measurements at the bedside, LiMAx facilitates informed decision-making for tailored medical treatments, thereby enhancing patient outcomes. The company has successfully used its technology with thousands of patients and is focused on expanding its global operations.

Capical GmbH specializes in the development and marketing of advanced electrocardiography (ECG) devices that utilize capacitive electrodes for contact-free patient monitoring. Founded in 2010 and based in Braunschweig, Germany, the company has established itself as a leader in capacitive sensor technology, which has applications beyond healthcare, including monitoring driver states in vehicles and physiological parameters in furniture such as chairs and beds. Capical's innovative approach allows for the continuous monitoring of heart and respiratory rates, cardiac arrhythmias, and other vital signs without direct skin contact, enhancing patient comfort and safety. The company also engages in extensive research and development to integrate its monitoring solutions into various products, supporting clients from initial prototyping to serial production. Capical has received several awards for its technological advancements and is recognized for its pioneering work in medically approved capacitive ECG devices, aiming to improve quality of life for elderly and ill individuals while also enhancing safety in automated driving scenarios.

Lophius Biosciences GmbH is a biotechnology company based in Regensburg, Germany, specializing in the development of innovative immune diagnostic systems aimed at enhancing the management and treatment of acute infectious and autoimmune diseases. Founded in 2002, the company focuses on immunology and T-cell diagnostics, offering a range of products including diagnostic kits, ready-to-use elispot kits, and various assay development services. Lophius Biosciences utilizes proprietary technologies, such as T-activation® and Reverse T Cell Technology, to stimulate immune effector cells and differentiate between active and memory T cells. These advancements support personalized treatment approaches and improve therapy control for patients, particularly in the fields of transplantation and infectious disease management. Additionally, the company provides custom services for bioactivity and quality testing of pharmaceutical agents, highlighting its commitment to advancing research and diagnostics in immunology.

EGYM is a global fitness technology company that specializes in providing intelligent workout solutions for fitness and health facilities. The company offers a comprehensive platform that integrates connected gym equipment and software, enabling operators to enhance the workout experience for their members. EGYM's offerings include a B2B corporate fitness subscription solution tailored for employers, as well as personalized, data-driven fitness experiences for users. This approach supports individuals in achieving their fitness goals, whether related to muscle gain, performance, or rehabilitation. EGYM's commitment to member success is reflected in its belief that the success of gym operators is intrinsically linked to the progress of their members towards improved physical and mental wellness.

GILUPI GmbH is a medical device company based in Potsdam, Germany, specializing in the development and production of diagnostic products for the in vivo isolation of rare cells from circulating blood. The company's devices are specifically designed to isolate tumor cells by utilizing antibodies bound to a nano-detector, allowing for precise identification of circulating tumor cells. This technology enables healthcare professionals to perform in vivo isolation, supporting tailored therapeutic approaches for patients. GILUPI's products are CE certified, ensuring compliance with European health standards.

Biametrics specializes in providing innovative research and development services aimed at the academia, pharmaceutical, biotechnology, and diagnostic markets. The company's products focus on label-free detection systems that characterize biomolecular interactions, offering valuable kinetic and thermodynamic data, including affinity measurements and specificity information. Biametrics' technology enables enhanced data evaluation for applications in diagnostics and process analytics, allowing clients to gain insights into biomolecular behavior with unmatched performance in throughput and versatility.

ChromoTek GmbH, founded in 2008 and based in Planegg-Martinsried, Germany, specializes in the development of innovative immunologic research reagents and tools for proteomics and cell biology. The company focuses on creating a new class of research tools derived from single domain camel antibodies, which are designed to enhance research capabilities in health institutions globally. By providing advanced tools for scientific research, ChromoTek aims to improve the quality and effectiveness of research outputs in the fields of cell biology and proteomics.

Lophius Biosciences GmbH is a biotechnology company based in Regensburg, Germany, specializing in the development of innovative immune diagnostic systems aimed at enhancing the management and treatment of acute infectious and autoimmune diseases. Founded in 2002, the company focuses on immunology and T-cell diagnostics, offering a range of products including diagnostic kits, ready-to-use elispot kits, and various assay development services. Lophius Biosciences utilizes proprietary technologies, such as T-activation® and Reverse T Cell Technology, to stimulate immune effector cells and differentiate between active and memory T cells. These advancements support personalized treatment approaches and improve therapy control for patients, particularly in the fields of transplantation and infectious disease management. Additionally, the company provides custom services for bioactivity and quality testing of pharmaceutical agents, highlighting its commitment to advancing research and diagnostics in immunology.

Delphi Optics GmbH is a Germany-based company that develops and distributes automatic, optical classification systems for medical applications. It was founded in 2009 and is headquartered in Lübeck, Schleswig-Holstein.

Humedics GmbH, founded in 2009 and based in Berlin, Germany, specializes in the development of a breath analysis device designed to assess liver function in patients suffering from liver failure. The company's key product, the LiMAx test, is a diagnostic system that includes a medical device, breath masks, and a diagnostic drug, enabling clinicians to quantitatively evaluate individual liver function. This technology supports various applications, such as assessing liver function before and after transplantation, planning liver surgeries, and evaluating conditions like liver cirrhosis. By providing rapid and precise measurements at the bedside, LiMAx facilitates informed decision-making for tailored medical treatments, thereby enhancing patient outcomes. The company has successfully used its technology with thousands of patients and is focused on expanding its global operations.

Public Health Solutions they provide services that improve the health of low-income, and high-risk families, and communities.

Lophius Biosciences GmbH is a biotechnology company based in Regensburg, Germany, specializing in the development of innovative immune diagnostic systems aimed at enhancing the management and treatment of acute infectious and autoimmune diseases. Founded in 2002, the company focuses on immunology and T-cell diagnostics, offering a range of products including diagnostic kits, ready-to-use elispot kits, and various assay development services. Lophius Biosciences utilizes proprietary technologies, such as T-activation® and Reverse T Cell Technology, to stimulate immune effector cells and differentiate between active and memory T cells. These advancements support personalized treatment approaches and improve therapy control for patients, particularly in the fields of transplantation and infectious disease management. Additionally, the company provides custom services for bioactivity and quality testing of pharmaceutical agents, highlighting its commitment to advancing research and diagnostics in immunology.

Sense Inside develops a unique diagnostic and therapeutic device specifically for bruxism, the condition characterized by involuntary teeth grinding. This innovative device aims to offer long-term solutions for both diagnosis and treatment, addressing the significant physiological strain experienced by an increasing number of patients. By equipping healthcare professionals with a comprehensive tool, Sense Inside enhances the ability to diagnose and manage dental diseases associated with bruxism.

awenydd diagnostics GmbH is a Germany-based company that analyzes patients and interactions they have with other drugs.

Public Health Solutions they provide services that improve the health of low-income, and high-risk families, and communities.

Scylab medic develops an environment sensing device for blind and visually impaired people. Its products include feelix, a light device that uses a 3D sensor to facilitate the user to partially recognize surroundings without physically touching, as well as to identify stationary and moving objects. The company was founded in 2006 and is based in Leipzig, Germany.

multiBIND biotec GmbH, founded in 2005 and located in Dortmund, Germany, specializes in developing innovative solutions for decontamination and disinfection. The company’s flagship technology, bioDECONT®, addresses issues related to horizontal gene transfer by effectively removing genetic material (DNA/RNA) and various biomolecules, including proteins and lipids. Additionally, multiBIND offers bioCLEAN, a range of antimicrobial and antiviral solutions, and CleanExtract, a tool designed for rapid determination of microbial ATP in diverse substances such as lubricants, oil emulsions, and paint. Through its focus on molecular genetics and biomedicine, multiBIND biotec aims to advance technologies and products that enhance safety and cleanliness in various applications.

awenydd diagnostics GmbH is a Germany-based company that analyzes patients and interactions they have with other drugs.